Physical activity on prescription (PAP): self-reported physical activity and quality of life in a Swedish primary care population, 2-year follow-up

Figures & data

Figure 1. Physical activity on prescription – participants’ flow chart.

Table 1. Baseline characteristics of the patients (n = 146) included in the study who have received PAP.

	n (%)	Mean (SD)
Women	109 (75)
Age (years) (n = 146)		55 (11)
BMI (kg/m^2) (n = 138)		30 (5.5)
Marital status^a (n = 85)	67 (79)
University education (n = 85)	21 (25)

Data are presented as mean, (standard deviation) or number with (percentage). BMI: body mass index; PAP: Physical activity on prescription.

^a Living with someone or married.

Table 2. Self-reported physical activity level according to the Saltin-Grimby Physical Activity Level Scale at baseline and at six, 12 and 24 months (M) after receiving physical activity on prescription.

	n	S (%)	LPA (%)	MVPA (%)	p-Value
Patients
Baseline	142	45 (32)	91 (64)	6 (4)
6 m	99	14 (14)	74 (75)	11 (11)	<.001
12 m	115	23 (20)	74 (64)	18 (16)	<.01
24 m	84	18 (21)	56 (67)	10 (12)	.093
Reference group
Baseline	55	9 (16)	36 (65)	10 (18)
6 m	34	7 (21)	20 (59)	7 (21)	.405
12 m	43	8 (19)	28 (65)	7 (16)	.739
24 m	34	7 (21)	20 (59)	7 (21)	.480

S: Sedentary/physically inactive; LPA: light physical activity; MVPA: moderate vigorous physical activity. The p value denotes significance for a positive change in PA level according to the McNemar test at follow-up compared with baseline.

Table 3. Mean changes in quality of life, measured by using SF-36, from baseline to six, 12 and 24 months follow-up among patients prescribed physical activity.

SF-36 Scale score	Study period, months	Mean value baseline (SD)	Mean difference (95% CI)	N
Physical functioning		66.7 (22.1)		143
	0–6		5.0 (0.8 to 9.3)	99
	0–12		1.9 (−1.9 to 5.7)	117
	0–24		3.7 (−0.5 to 7.8)	82
Role limitation, physical		42.6 (42.0)		141
	0–6		15.4 (6.6 to 24.3)	94
	0–12		18.3 (9.9 to 26.7)	113
	0–24		14.0 (5.6 to 22.3)	80
Bodily pain		44.9 (27.5)		145
	0–6		10.4 (4.9 to 15.8)	102
	0–12		7.2 (2.0 to 12.3)	119
	0–24		9.3 (3.6 to 14.9)	83
General health		52.1 (20.5)		145
	0–6		3.9 (0.7 to 7.0)	102
	0–12		4.3 (1.4 to 7.3)	119
	0–24		5.7 (2.0 to 9.3)	84
Vitality		46.5 (23.3)		145
	0–6		4.1 (0.2 to 8.0)	101
	0–12		5.2 (1.5 to 8.9)	119
	0–24		5.1 (0.5 to 9.6)	84
Social functioning		68.9 (27.9)		146
	0–6		6.9 (2.4 to 11.4)	103
	0–12		4.8 (−0.5 to 10.0)	121
	0–24		5.0 (−1.1 to 11.1)	85
Role limitation, emotional		59.7 (42.8)		136
	0–6		3.8 (−5.0 to 12.6)	92
	0–12		5.0 (−2.6 to 12.6)	107
	0–24		7.9 (−2.0 to 17.8)	80
Mental health		66.0 (24.7)		145
	0–6		2.7 (−0.7 to 6.0)	100
	0–12		3.7 (0.6 to 6.9)	119
	0–24		0.5 (−3.2 to 4.2)	85
Physical component summary		37.3 (10.6)		134
	0–6		4.2 (2.1 to 6.3)	91
	0–12		3.3 (1.3 to 5.4)	103
	0–24		3.8 (1.5 to 6.1)	76
Mental component summary		42.7 (14.5)		134
	0–6		0.6 (−1.6 to 2.8)	91
	0–12		1.4 (−0.7 to 3.5)	103
	0–24		1.4 (−1.3 to 4.1)	76

The scale score are between 0 (worst) and 100 (best). SD: standard deviation; CI: confidence interval.

Table 4. Mean changes in quality of life from baseline to 24-month follow-up among the reference group.

SF-36 Scale score	Study period, months	Mean value baseline (SD)	Mean difference (95% CI)	N
Physical functioning		76.8 (25.5)		54
	0–24		−0.1 (−6.9 to 6.8)	35
Role limitation, physical		61.7 (42)		52
	0–24		−1 (−19.3 to 17.4)	34
Bodily pain		57.3 (32.6)		54
	0–24		6.9 (−2.4 to 16.3)	35
General health		60.3 (22.5)		54
	0–24		2.8 (−3.9 to 9.6)	35
Vitality		53.5 (26.5)		54
	0–24		1.8 (−6.4 to 10)	35
Social functioning		70.4 (29)		54
	0–24		6.9 (−2.8 to 16.7)	35
Role limitation, emotional		62.2 (42.8)		52
	0–24		11.4 (−7.2 to 30)	34
Mental health		66.6 (23.8)		54
	0–24		2.7 (−4.1 to 9.5)	35
Physical component summary		44.4 (11.7)		52
	0–24		−0.6 (−4.3 to 3.1)	34
Mental component summary		41.5 (15.2)		52
	0–24		3.9 (−1.3 to 9.1)	34

SD: standard deviation; CI: confidence interval.